Literature DB >> 2523938

Recombinant soluble Fc epsilon receptor II (Fc epsilon RII/CD23) has IgE binding activity but no B cell growth promoting activity.

N Uchibayashi1, H Kikutani, E L Barsumian, R Hauptmann, F J Schneider, R Schwendenwein, W Sommergruber, W Spevak, I Maurer-Fogy, M Suemura.   

Abstract

We have undertaken the production of recombinant soluble Fc epsilon receptor II (Fc epsilon RII) as a secretory protein, but not as a cleavage product of membrane-bound receptor. Several plasmid constructs containing soluble receptor sequence were prepared. Only a chimeric gene containing the sequences encoding IL-6 signal peptide and the soluble moiety of Fc epsilon RII could be expressed in Xenopus laevis oocytes and CHO cells, resulting in the secretion of soluble Fc epsilon RII. The recombinant soluble Fc epsilon RII was also produced in the yeast expression system. The NH2-terminal sequence analysis of the chimeric gene product generated by oocytes demonstrated the correct cleavage of IL-6 leader sequence by a signal peptidase. Moreover, most of CHO cell and all of the yeast-derived recombinant molecules were products identical with the native B cell-derived soluble Fc epsilon RII. These recombinant products as well as the natural soluble receptor derived from a human B cell line could bind both human IgE and two different anti-Fc epsilon RII mAb and could competitively inhibit the binding of IgE to Fc epsilon RII-expressing cells. However, the recombinant soluble Fc epsilon RII and highly purified native molecules did not display any B cell growth-promoting activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2523938

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

1.  Activity of soluble factors produced by Epstein-Barr virus-transformed human B lymphocytes on different cell lines.

Authors:  C Garzelli; A Bazzichi
Journal:  Experientia       Date:  1991-07-15

2.  Immunohistochemical demonstration of CD23 expression on lymphocytes in rheumatoid synovitis.

Authors:  E A Hellen; D C Rowlands; T T Hansel; G D Kitas; J Crocker
Journal:  J Clin Pathol       Date:  1991-04       Impact factor: 3.411

3.  Defective expression of CD23 and autocrine growth-stimulation in Epstein-Barr virus (EBV)-transformed B cells from patients with Wiskott-Aldrich syndrome (WAS).

Authors:  H U Simon; E A Higgins; M Demetriou; A Datti; K A Siminovitch; J W Dennis
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

4.  Induction of B cell responsiveness to growth factors by Epstein-Barr virus conversion: comparison of endogenous factors and interleukin-1.

Authors:  B A Blazar; A M Murphy
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

5.  Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells.

Authors:  G Tosato; J Tanner; K D Jones; M Revel; S E Pike
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

6.  The absence of IgE antibody-mediated augmentation of immune responses in CD23-deficient mice.

Authors:  H Fujiwara; H Kikutani; S Suematsu; T Naka; K Yoshida; K Yoshida; T Tanaka; M Suemura; N Matsumoto; S Kojima
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

7.  Comparison of the carbohydrate moieties of recombinant soluble Fc epsilon receptor (sFc epsilon RII/sCD23) expressed in Saccharomyces cerevisiae and Chinese hamster ovary cells. Different O-glycosylation sites are used by yeast and mammalian cells.

Authors:  I Kalsner; F J Schneider; R Geyer; H Ahorn; I Maurer-Fogy
Journal:  Glycoconj J       Date:  1992-08       Impact factor: 2.916

Review 8.  Expression, regulation and function of human Fc epsilon RII (CD23) antigen.

Authors:  M Sarfati; S Fournier; C Y Wu; G Delespesse
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

9.  Lymphotoxin is an autocrine growth factor for Epstein-Barr virus-infected B cell lines.

Authors:  Z Estrov; R Kurzrock; E Pocsik; S Pathak; H M Kantarjian; T F Zipf; D Harris; M Talpaz; B B Aggarwal
Journal:  J Exp Med       Date:  1993-03-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.